Result of AGM

RNS Number : 7374I

Sareum Holdings PLC

15 December 2020

 

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 15 December 2020 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, held its Annual General Meeting ("AGM") today and all resolutions were duly passed on a poll. Details of the proxy voting are shown in the table below. 

Ordinary resolutions	Votes For	%	Votes Against	%	Votes Total	% of ISC Voted	Votes Withheld
1. Receive the Annual report and accounts for the Company	236,539,335	99.97	76,912	0.03	236,616,247	7.24	317,483
2. Approve the Directors' Remuneration Report	225,264,050	98.71	2,946,682	1.29	228,210,732	6.98	8,722,998
3. Re-elect Dr Stephen Parker as a director	225,888,456	95.36	10,980,647	4.64	236,869,103	7.25	64,627
4. Re-elect Dr Tim Mitchell as a director	236,331,048	99.77	538,055	0.23	236,869,103	7.25	64,627
5. Appoint Shipleys LLP as auditor	236,450,012	99.80	483,718	0.20	236,933,730	7.25	0
6. Directors' authority to allot new shares	229,589,440	97.03	7,026,807	2.97	236,616,247	7.24	317,483
Special Resolution
7. Disapplication of pre-emption rights	229,229,425	96.90	7,322,195	3.10	236,551,620	7.24	382,110

ISC - Issued Share Capital

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

For further information, please contact:

Sareum Holdings plc Tim Mitchell, CEO	01223 497 700
Strand Hanson Limited (Nominated Adviser) James Dance / Richard Tulloch	020 7409 3494
Hybridan LLP (Nominated Broker) Claire Noyce / John Beresford-Peirse	020 3764 2341
Citigate Dewe Rogerson (Financial PR) Mark Swallow/ David Dible	020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

 

END

 

 

RAGKKPBPBBDDOBD